2026 年至 2032 年肝病治疗市场（依肝病类型、治疗类型及地区划分）

肝病治疗市场评估-2026-2032

全球肝病盛行率的上升是由不良生活习惯、饮酒以及病毒性肝炎感染率上升等因素造成的。随着这些疾病的恶化，对有效治疗方法来管理和治疗肝病的需求日益增长。新兴国家医疗基础设施的不断扩大和医疗支出的不断增长，提高了人们获得改进的肝病治疗方案和治疗方法的管道，从而推动了市场扩张。预计到2024年，肝病市场规模将达到160.9亿美元，到2032年将达到390.4亿美元。

此外，医学研究和技术的进步正在推动创新药物的发展，例如靶向生技药品和基因疗法，这些药物有可能改善治疗效果并满足肝病领域未满足的医疗需求。预计从 2026 年到 2032 年，该市场将以约 11.72% 的复合年增长率 (CAGR) 成长。

肝病治疗市场定义/概述

肝病治疗包括用于管理和治疗肝炎、脂肪肝、肝硬化和肝癌等肝病的疗法和药物。抗病毒药物、免疫抑制剂和肝臟移植是可用的治疗方法。它们在治疗实践中的应用包括预防疾病发作、控制症状和提高患者的生活品质。肝病治疗的未来前景光明，目前正在进行的研究重点是开发标靶治疗、个人化和再生疗法，以提高疗效并减少副作用，最终改善全球患者的预后。

肝病盛行率的上升是否会推动肝病治疗市场的发展？

肝病盛行率的上升预计将显着推动肝病治疗市场的发展。肝病包括病毒性肝炎、非酒精性脂肪肝病 (NAFLD)、酒精性肝病、肝硬化、肝癌等。根据政府最新统计数据，肝病已成为全球性健康问题。世界卫生组织 (WHO) 的数据显示，到 2023 年，肝病每年将导致近 200 万人死亡。

美国，美国疾病管制与预防中心（CDC）报告称，慢性肝病和肝硬化是美国第九大死亡原因，年龄调整后的死亡率为每十万人13.5人。

世界各国政府也积极采取措施应对日益增长的肝病盛行率。为遏止肝病的发生和发展，各国已开展了倡导改变生活方式、推行肝炎疫苗接种计画和减少饮酒政策的公共卫生宣传活动。这些活动对于改变监管格局和促进肝病治疗的商业性成长至关重要。 2024年1月，英国国家医疗服务体系（NHS）启动了一项全国性的肝臟健康筛检计划，旨在及早发现肝病，减轻医疗系统的负担。

肝病治疗市场前景光明，精准医疗和标靶治疗的研究正在进行中。基因编辑和生物标记发现等生物技术创新有望改变肝病患者的治疗策略，提供量身定制、更有效的解决方案。 2024年2月，史丹佛大学的研究人员在《自然》杂誌上发表了一篇开创性的论文，揭示了可以预测NAFLD进展为更严重肝病的基因标记。

人们对抗药性的日益担忧是否会阻碍肝病治疗市场的成长？

肝病盛行率的不断上升预计将推动肝病治疗市场蓬勃发展。抗药性是指病毒和细菌等微生物对用于治疗的药物产生抗药性，从而降低现有治疗的有效性。对于肝病，尤其是病毒性肝炎，B肝病毒 (HBV) 和C型肝炎病毒(HCV) 等抗药性菌株的出现是治疗的一大障碍。这些抗药性菌株限制了治疗选择，导致治疗失败，加重病情，并增加医疗支出。

近期研究表明，肝炎病毒存在抗药性。例如，在B肝病毒中，长期服用抗病毒药物可能导致抗药性突变的形成，从而降低常规用于抑制病毒复製的核苷（酸）类似物的疗效。同样，儘管目前已有用于治疗丙肝的直接抗病毒药物 (DAA)，但仍有抗药性突变的报道，因此需要密切监测，并可能需要调整治疗方法。

製药公司和学术机构正在积极研究新型抗病毒药物和联合治疗，以对抗抗药性。然而，由于成本高昂且开发週期长，此类努力面临经济上的担忧。此外，监管机构对安全性和有效性的证明要求严格，这使得新治疗方法的市场准入变得复杂。

各国政府和医疗机构也积极开展预防倡议，以应对抗药性问题，包括推广肝炎病毒疫苗、建立早期检测筛检项目，以及培训医护人员和患者遵守治疗方案。然而，应对抗药性需要持续投入研究、监测和医疗基础设施建设，这可能会对医疗预算和资源造成压力。

目录

第一章 引言

• 市场定义
• 市场区隔
• 调查方法

第二章执行摘要

• 主要发现
• 市场概览
• 市集亮点

第三章市场概述

• 市场规模和成长潜力
• 市场趋势
• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析

第四章 肝病治疗市场（依肝病类型）

• 肝炎
• 非酒精性脂肪肝（NAFLD）
• 酒精性肝病（ALD）
• 肝硬化
• 肝癌（肝细胞癌）

第五章肝病治疗市场（依治疗类型）

• 药物治疗
• 肝臟移植
• 营养和生活方式干预
• 干涉

第六章区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利
• 亚太地区
• 中国
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯聯合大公国

第七章市场动态

• 市场驱动因素
• 市场限制
• 市场机会
• COVID-19 市场影响

第八章 竞争态势

• 主要企业
• 市场占有率分析

第九章 公司简介

• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Gilead Sciences, Inc.
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Novartis AG
• Johnson & Johnson
• Celgene Corporation
• Samsung Bioepis Co., Ltd.

第十章 市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第十一章 市场展望 附录

• 简称列表
• 来源和参考文献

Liver Diseases Therapeutics Market Valuation - 2026-2032

The increasing global prevalence of liver illnesses is being driven by factors such as poor lifestyles, alcohol consumption, and an increase in viral hepatitis infections. As these disorders worsen, there is a greater need for effective therapies to manage and treat liver illnesses. Expanding healthcare infrastructure and rising healthcare expenditure in emerging countries help to drive market expansion by improving access to improved treatments and therapies for liver diseases. USD 16.09 Billion in 2024 and reaching USD 39.04 Billion by 2032.

Furthermore, advances in medical research and technology are resulting in the development of innovative medicines, such as targeted biologics and gene therapies, which show promise for improving treatment results and addressing unmet medical requirements in liver disease management growth is expected to grow at a CAGR of about 11.72% from 2026-2032.

Liver Diseases Therapeutics Market: Definition/ Overview

Liver disease therapeutics include treatments and drugs for managing and curing liver illnesses such as hepatitis, fatty liver disease, cirrhosis, and liver cancer. Antiviral medications, immunosuppressants, and liver transplant procedures are among the available treatments. Their applications in therapeutic settings include avoiding disease development, controlling symptoms, and increasing patient quality of life. The future of liver disease therapeutics seems optimistic, with continuing research focusing on creating targeted medications, personalized medicine methods, and regenerative treatments that aim to improve efficacy and reduce adverse effects, ultimately improving patient outcomes worldwide.

Will Rising Prevalence of Liver Disorders Propel the Liver Diseases Therapeutics Market?

The rising prevalence of liver disorders is predicted to considerably drive the Liver disorders Therapeutics Market. Liver diseases include viral hepatitis, nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease, cirrhosis, and liver cancer. According to recent government figures, liver illnesses are becoming a major global health concern. According to the World Health Organization (WHO), liver disorders will kill nearly 2 million people annually by 2023.

In 2024, the Centers for Disease Control and Prevention (CDC) reported that chronic liver disease and cirrhosis were the ninth largest cause of death in the United States, with an age-adjusted death rate of 13.5 per 100,000 people.

Governments around the world are also taking aggressive steps to address the increased prevalence of liver ailments. To reduce the incidence and progression of liver disease, public health campaigns advocating lifestyle modifications, hepatitis virus immunization programs, and alcohol-reduction policies are being introduced. These activities are critical for changing the regulatory landscape and driving commercial growth for liver disease therapies. In January 2024, the UK's National Health Service (NHS) launched a nationwide liver health screening program, with the goal of detecting liver disorders at an earlier stage and reducing the strain on the healthcare system.

The future of the liver diseases therapeutics market appears bright, with continuous research concentrating on precision medicine methods and targeted therapeutics. Biotechnology innovations, such as gene editing techniques and biomarker discoveries, are likely to transform therapy tactics for people with liver illnesses, providing tailored and more effective solutions. Collaboration among governments, healthcare providers, and pharmaceutical companies is critical in driving progress and assuring access to quality care, ultimately improving outcomes and lowering the global burden of liver disorders. in February 2024, Stanford University researchers released a groundbreaking paper in Nature, revealing a collection of genetic markers that can predict the progression of NAFLD to more severe forms of liver disease, opening the door to tailored treatment techniques.

Will Growing Fears Regarding Drug Resistance Hamper the Growth of the Liver Diseases Therapeutics Market?

Growing prevalence of liver diseases is projected to upsurge the liver diseases therapeutics market. Drug resistance occurs when microorganisms, such as viruses or bacteria, develop resistance to the medications used to treat them, lowering the efficacy of current therapy. In the context of liver illnesses, particularly viral hepatitis, the rise of drug-resistant strains like hepatitis B virus (HBV) and hepatitis C virus (HCV) presents considerable hurdles. These resistant strains can limit treatment options and cause treatment failures, aggravating disease progression and driving up healthcare expenditures.

Recent research has demonstrated the incidence of medication resistance in hepatitis viruses. For instance, in hepatitis B, extended antiviral medication might result in the formation of resistance mutations, lowering the efficiency of nucleos(t)ide analogs routinely employed to inhibit viral reproduction. Similarly, despite the availability of direct-acting antiviral (DAA) medicines for hepatitis C, there have been reports of resistance mutations, needing close monitoring and possibly treatment regimen changes.

Pharmaceutical companies and academic organizations are aggressively researching novel antiviral medicines and combination therapies to combat medication resistance. However, the high expenses and long development schedules connected with these initiatives provide economic concerns. Furthermore, regulatory bodies have strict requirements for showing safety and efficacy, complicating the entry of new therapies to the market.

Governments and healthcare groups are also working on prevention initiatives to combat medication resistance. These include promoting hepatitis virus vaccine, creating early detection screening programs, and training healthcare practitioners and patients on treatment protocol adherence. However, combating drug resistance necessitates ongoing investment in research, surveillance, and healthcare infrastructure, which may strain healthcare budgets and resources.

Category-Wise Acumens

Will Rising Prevalence of Hepatitis Worldwide the Liver Diseases Therapeutics Market?

The increasing frequency of hepatitis worldwide is expected to have a substantial impact on the Liver Diseases Therapeutics Market. Hepatitis, particularly hepatitis B and C viruses (HBV and HCV), is still a serious global health concern, impacting millions of people. According to a WHO research, immunization, diagnostic tests, medicines, and information campaigns could avert approximately 4.5 million premature deaths in low- and middle-income countries by 2030. WHO's global hepatitis plan, which is supported by all WHO Member States, seeks to reduce new hepatitis infections by 90% and fatalities by 65% between 2016 and 2030.

Recent advancements in the pharmaceutical industry highlight substantial progress in combating hepatitis. For instance, in June 2023, AbbVie published encouraging findings from a phase 3 trial of its innovative pan-genotypic hepatitis C therapy, which demonstrated high efficacy rates across many patient populations. This study highlights ongoing attempts to improve treatment options and efficacy in battling hepatitis C, a key contributor to the liver diseases therapeutics Market.

Governments and international health organizations are also stepping up efforts to prevent hepatitis through comprehensive public health policies. The World Health Organization (WHO) has set lofty goals for ending viral hepatitis as a public health issue by 2030. These activities include increasing access to cheap diagnostic equipment, treatments, and vaccines, as well as supporting preventative measures including safe injection practices and hepatitis B vaccination programs.

Meanwhile, the most rapidly developing categories are non-alcoholic fatty liver disease (NAFLD) and its advanced version, non-alcoholic steatohepatitis (NASH). The global rise in obesity and metabolic syndrome has resulted in an increased incidence of NAFLD/NASH, which is projected to boost demand for treatments that target these disorders. Alcoholic Liver Disease (ALD), Liver Cirrhosis, and Liver Cancer (Hepatocellular Carcinoma) are also substantial market sectors, owing to developments in treatment options and increasing awareness, particularly in regions with high alcohol consumption and hepatitis prevalence.

Will Increasing Adoption of Pharmacotherapy Propel the Liver Diseases Therapeutics Market?

The growing use of pharmacotherapy is likely to boost the liver diseases therapeutics market significantly. Pharmacotherapy, which includes antivirals, immunosuppressants, and chemotherapeutic drugs, is essential in the treatment of a variety of liver illnesses, including hepatitis, non-alcoholic fatty liver disease (NAFLD), and liver cancer. In 2023 According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), pharmaceutical therapies will be used to manage more than 60% of patients with chronic liver disease. This shift is being driven by the advancement of more effective and tailored drugs that can halt disease progression, manage symptoms, and, in some cases, reverse liver damage.

Governments around the world are increasingly emphasizing healthcare investments to combat liver illnesses. In the Asia-Pacific area, governments are adopting comprehensive immunization programs and treatment measures to eradicate hepatitis and reduce disease burden, which is driving up market demand for pharmacotherapy. In March 2024, Gilead Sciences received FDA clearance for a novel combination medication for chronic hepatitis B, which is estimated to earn over $1 billion in annual sales by 2026.

Meanwhile, interventional procedures are the fastest increasing area, thanks to advances in minimally invasive approaches for treating liver tumors and cirrhosis problems such as radiofrequency ablation, transarterial chemoembolization (TACE), and selective internal radiation therapy (SIRT). These techniques offer effective therapeutic alternatives, reducing recovery periods and increasing patient outcomes, resulting in increased acceptance in clinical practice. Nutritional and lifestyle interventions, as well as liver transplantation, continue to play an important role in the market, focusing on disease prevention, management, and increasing patient survival rates.

Country/Region-wise

Will Rising Advanced Healthcare Infrastructure in North America Drive the Liver Diseases Therapeutics Market?

The growing modern healthcare infrastructure in North America is expected to drive significant growth in the liver diseases therapeutics market. The region's well-established healthcare systems, combined with significant investments in medical R&D, foster innovation and adoption of innovative therapies. Recent figures highlight North America's robust healthcare expenditure, which helps to develop and implement cutting-edge liver disease therapies.

In recent years, North America has seen significant advances in liver disease treatment. For instance, in October 2023, AbbVie announced FDA clearance for their novel hepatitis C treatment regimen, which combines two direct-acting antivirals (DAAs) with different modes of action. This approval underscores continuous efforts in the region to improve treatment efficacy and patient outcomes. Such developments profit from shipments benefit from North America's strict regulatory environment and advanced healthcare infrastructure, which allow for fast approvals and widespread uptake of new therapies.

Furthermore, the region's emphasis on precision medicine and individualized therapeutics is changing the face of liver disease therapy. For instance, in March 2024, Regeneron Pharmaceuticals reported positive Phase 3 findings for a genetically targeted medication for a subpopulation of non-alcoholic steatohepatitis (NASH) patients, with a 40% improvement in liver fibrosis compared to usual care. This news resulted in a 15% increase in the company's stock price, demonstrating the market's enthusiasm for precision methods to liver disease therapy.

Will Rising Healthcare Expenditure in Asia-Pacific Boost the Liver Diseases Therapeutics Market?

Rising healthcare expenditure in the Asia-Pacific region is predicted to significantly enhance the liver diseases therapeutics market. As Asia-Pacific economies grow, so does healthcare spending, with the goal of enhancing healthcare infrastructure, expanding access to medical services, and tackling the rising burden of chronic diseases, such as liver disease. Recent figures show significant investments in healthcare across the region, emphasizing the potential for market growth in liver disease therapies.

For instance, in recent years, countries such as China and India have seen significant rises in healthcare spending. In July 2023, China announced intentions to invest around USD 2.3 Trillion yuan (approximately USD 360 Billion USD) in healthcare reforms over the following few years, with a focus on expanding medical services and implementing innovative therapies. Similarly, India has increased healthcare investments, including steps to strengthen healthcare infrastructure and enhance access to critical drugs and treatments.

These efforts are critical in addressing Asia-Pacific's rising liver disease prevalence. Hepatitis, particularly hepatitis B and C, is a major health concern in the region. Recent company news emphasizes advances in therapy options to combat severe disorders. For instance, in September 2023, Gilead Sciences published favorable clinical trial findings for its new hepatitis C drug, which showed high efficacy and safety profiles in Asian populations. These advancements demonstrate the pharmaceutical industry's dedication to fulfilling the region's healthcare needs while also driving market growth in liver disease therapies.

Furthermore, regulatory reforms and policies that promote healthcare innovation are helping industry growth. Countries in Asia-Pacific are streamlining regulatory processes to speed up the approval and adoption of novel cures, increasing market competitiveness and promoting investment in R&D. These initiatives are intended to provide a favorable environment for pharmaceutical companies to introduce new medicines and increase their market position in liver disease therapy.

Competitive Landscape

The competitive landscape of the liver diseases therapeutics market is characterized by intense research and development activities aimed at advancing treatment options for various liver conditions. The numerous pharmaceutical companies, biotechnology firms, and academic institutions are actively involved in developing novel therapies and enhancing existing treatments. Regulatory approvals and clinical trials play a crucial role in shaping market dynamics, with companies focusing on differentiated approaches such as personalized medicine, targeted therapies, and immunomodulatory drugs to address the diverse needs of patients. Additionally, collaborations between industry players and healthcare providers contribute to the expansion of treatment options and the improvement of patient outcomes in this competitive market segment.

Some of the prominent players operating in the liver diseases therapeutics market include:

• AbbVie, Inc.
• Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Gilead Sciences, Inc.
• Bristol-Myers Squibb Company
• Pfizer, Inc.
• Novartis AG

Latest Developments

• In December 2023, Pfizer acquired Akero medicines for $7.3 billion, expanding its footprint in the liver disease medicines sector. Akero's primary candidate, efruxifermin, a FGF21 mimic used to treat NASH, has showed good results in Phase 2b trials. This acquisition demonstrates the increasing prominence of NASH in the pharmaceutical industry's pipeline.
• In November 2023, Intercept Pharmaceuticals reported 5-year follow-up results from the POISE trial of Ocaliva (obeticholic acid) in primary biliary cholangitis (PBC) at the American Association for the Study of Liver Diseases (AASLD) annual meeting. The data showed prolonged improvement in liver biochemistry and a lower risk of liver transplantation or mortality, confirming the treatment's long-term efficacy for PBC.
• In January 2024, Alnylam got FDA approval for Givlaari (givosiran), an RNAi therapy for acute hepatic porphyria. This is a substantial progress in the application of RNA interference technology to liver diseases, providing a new therapy option for a rare but severe liver condition. The approval was based on Phase 3 trial data, which revealed a 74% reduction in yearly porphyria attack rates.

Liver Diseases Therapeutics Market, By Category

• Type of Liver Disease:
• Hepatitis
• Non-alcoholic Fatty Liver Disease (NAFLD)
• Alcoholic Liver Disease (ALD)
• Liver Cirrhosis
• Liver Cancer (Hepatocellular Carcinoma)
• Type of Therapy:
• Pharmacotherapy
• Liver Transplantation
• Nutritional and Lifestyle Interventions
• Interventional Procedures
• Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Liver Diseases Therapeutics Market, By Type of Liver Disease

• Hepatitis
• Non-alcoholic Fatty Liver Disease (NAFLD)
• Alcoholic Liver Disease (ALD)
• Liver Cirrhosis
• Liver Cancer (Hepatocellular Carcinoma)

5. Liver Diseases Therapeutics Market, By Type of Therapy

• Pharmacotherapy
• Liver Transplantation
• Nutritional and Lifestyle Interventions
• Interventional Procedures

6. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

7. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

8. Competitive Landscape

• Key Players
• Market Share Analysis

9. Company Profiles

• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Gilead Sciences, Inc.
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Novartis AG
• Johnson & Johnson
• Celgene Corporation
• Samsung Bioepis Co., Ltd.

10. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

11. Appendix

• List of Abbreviations
• Sources and References